Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Aspirin i subklinisk koronararteriesygdom: Et pilotstudie med randomiseret kontrol (ASCAD-P)

10. november 2026 opdateret af: Guillaume Marquis-Gravel, Montreal Heart Institute

Aspirin ved subklinisk koronararteriesygdom: Et pilot randomiseret kontrolleret forsøg

In patients with subclinical coronary artery disease, the ASCAD-P study aims to assess the feasibility of a larger phase 3 pragmatic randomized controlled trial comparing prescription versus no prescription of low-dose aspirin in routine clinical practice.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Cardiovascular disease remains the leading cause of mortality worldwide. Recent large randomized trials have demonstrated limited net clinical benefit of aspirin in unselected primary prevention populations, leading to guideline recommendations against its systematic routine use for cardiovascular protection.

Patients with subclinical coronary artery disease represent a high-risk subgroup. These individuals have documented coronary artery disease but have not experienced overt cardiovascular events or undergone revascularization. Observational data suggest that this population carries a substantially increased risk of myocardial infarction compared with individuals without coronary atherosclerosis. However, the benefit-risk balance of aspirin in this intermediate-risk group remains uncertain

Primary Objective:

To evaluate the recruitment rate of a pilot randomized trial comparing low-dose aspirin prescription versus no prescription.

Secondary Objectives

To evaluate key feasibility metrics, including:

  • The proportion of eligible patients who are randomized;
  • Adherence and persistence to the assigned intervention at 12 months;
  • The proportion of patients who do not complete the 12-month follow-up;
  • Barriers to recruitment, adherence, and retention.

Exploratory Objectives:

To explore clinical outcomes at 12 months, including:

  • The incidence of clinically significant bleeding events (BARC type 2, 3, or 5) and bleeding site;
  • The incidence of major adverse cardiovascular events (MACE), defined as a composite of all-cause mortality, non-fatal myocardial infarction, non-fatal stroke, or coronary revascularization;
  • Individual components of the composite endpoint;
  • Cardiovascular mortality;
  • Adverse Events and Serious Adverse Events.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

48

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • Quebec
      • Montreal, Quebec, Canada, H1T 1C8
        • Rekruttering
        • Montreal Heart Institute
        • Ledende efterforsker:
          • Guillaume Marquis-Gravel, MD, MSc
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Pierre Elias, MD
        • Ledende efterforsker:
          • Cyril Gagnon, MD
        • Ledende efterforsker:
          • Alino Demean Loghin, MD
      • Québec, Quebec, Canada, G1V 4G5
        • Ikke rekrutterer endnu
        • Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ)
        • Ledende efterforsker:
          • Tomas Cieza, MD
        • Ledende efterforsker:
          • Roubie Dib, MD
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Sara Desjardins, MD
      • Trois-Rivières, Quebec, Canada, G8Z 3R9
        • Ikke rekrutterer endnu
        • Centre hospitalier affilié universitaire régional (CHAUR)
        • Ledende efterforsker:
          • Vincent Spagnoli, MD
        • Kontakt:
        • Ledende efterforsker:
          • Farzin Brian Haghighat

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

40 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Documented coronary atherosclerosis, as defined by one of the following criteria:

    1. Coronary artery calcium (CAC) score > 0;
    2. Cardiac CT angiography (CCTA) / CoroScan: lesions <70% in the right coronary (RCA), left anterior descending (LAD), and circumflex (Cx) arteries or their branches, and <50% in the left main coronary artery;
    3. Coronary angiography: lesions <70% in the right coronary (RCA), left anterior descending (LAD), and circumflex (Cx) arteries or their branches, and <50% in the left main coronary artery; if performed, physiological coronary assessments (FFR, dPR, iFR, etc.) and intracoronary imaging (IVUS or OCT) must be negative for significant disease.
  2. Willing and able to provide informed consent and comply with study procedures

Exclusion Criteria:

  1. History of myocardial infarction (MI), coronary revascularization, stroke, transient ischemic attack (TIA), or peripheral arterial revascularization procedure;
  2. Current prescription or clear indication for aspirin, low-molecular-weight heparin (LMWH), direct oral anticoagulants, or any other antithrombotic medication;
  3. Clear contraindication to aspirin;
  4. History of significant bleeding within the past year;
  5. Severe illness with limited life expectancy (i.e., <5 years);
  6. Any condition that, in the investigator's judgment, would make participation unsafe for the patient.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Low-dose Aspirin Prescription

Aspirin 81 mg orally once daily prescription

Aspirin 81 mg orally once daily

Andet: No Prescription

No prescription of aspirin 81 mg orally once daily

No prescription of aspirin 81 mg orally once daily

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Monthly Recruitment Rate
Tidsramme: 12 months following study enrollment initiation

Average monthly patient recruitment rate:

0 ≤ Mean rate (patients/month) < 2 = study not feasible; 2 ≤ Mean rate (patients/month) < 4 = study feasible with protocol modifications;

≥ 4 Mean rate (patients/month) = study feasible without major protocol modifications.

12 months following study enrollment initiation

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Barrierer for rekruttering, overholdelse og patienttilbageholdelse
Tidsramme: Fra rekruttering til opfølgningens afslutning (12 måneder)
Fra rekruttering til opfølgningens afslutning (12 måneder)
Proportion of Eligible Patients Randomized
Tidsramme: 12 months following study enrollment initiation

Proportion of eligible patients who are randomized:

0% ≤ Proportion < 30% = study not feasible, major protocol modifications required; 30% ≤ Proportion < 61% = study feasible with protocol modifications;

≥ 61% = study feasible without protocol modifications.

12 months following study enrollment initiation
Intervention Adherence
Tidsramme: From randomization to the end of follow-up (12 months)

Proportion of days on which patients take the assigned intervention (adherence):

0% ≤ Mean proportion < 25% = study not feasible, major protocol modifications required; 25% ≤ Mean proportion < 74% = study feasible with protocol modifications;

≥ 74% = study feasible without protocol modifications.

From randomization to the end of follow-up (12 months)
Intervention Persistence
Tidsramme: From randomization to end of follow-up (12 months)

Proportion of patients who still take the assigned intervention at 12 months of follow-up (persistence):

0% ≤ Proportion < 25% = study not feasible, major protocol modifications required; 25% ≤ Proportion < 70% = study feasible with protocol modifications;

≥ 70% = study feasible without protocol modifications.

From randomization to end of follow-up (12 months)
Proportion of Patients Lost to Follow-up
Tidsramme: End of follow-up (12 months)

Proportion of patients who do not complete the 12-month follow-up visit:

≥ 10% = study not feasible, major protocol modifications required; 6% ≤ Proportion < 10% = study feasible with protocol modifications; 0% ≤ Proportion < 6% = study feasible without protocol modifications.

End of follow-up (12 months)

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Blødningsrate (BARC 2, 3, 5)
Tidsramme: Fra tilmelding til opfølgningens afslutning (12 måneder)
Fra tilmelding til opfølgningens afslutning (12 måneder)
Bivirkningsrate (AE) og alvorlig bivirkningsrate (SAE)
Tidsramme: Fra tilmelding til opfølgningens afslutning (12 måneder)
Fra tilmelding til opfølgningens afslutning (12 måneder)
Major Adverse Cardiovascular Event (MACE) Rate
Tidsramme: From enrollment to the end of follow-up (12 months)

MACE rate (all-cause mortality, non-fatal myocardial infarction, non-fatal stroke, or coronary revascularization) at 12 months of follow-up

From enrollment to the end of follow-up (12 months)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

21. juli 2026

Primær færdiggørelse (Anslået)

21. juli 2027

Studieafslutning (Anslået)

1. januar 2028

Datoer for studieregistrering

Først indsendt

5. april 2026

Først indsendt, der opfyldte QC-kriterier

5. april 2026

Først opslået (Faktiske)

13. april 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

12. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 2026-3694

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .